Retatrutide is primarily being developed for obesity treatment, with TRIUMPH trials focusing on weight loss in people with and without diabetes
If you feel your current dose is insufficient, dose escalation within the approved range (up to 15 mg weekly) is the standard clinical approach
India GLP-1 Receptor Agonists Obesity Drugs Market Insight The India GLP-1 receptor agonists obesity drugs accounted for the largest revenue share in Asia Pacific in 2024, driven by a growing obesity burden, increasing healthcare awareness, and the rapid expansion of urban healthcare infrastructure
GHRPs, including GHRP-2, can stimulate the release of adrenocorticotropic hormone (ACTH) and consequently cortisol , and can also raise prolactin , particularly at higher doses
Bn khng nn t ung cc loi thc phm chc nng tr nm trong giai on ny m hy i sau khi cai sa b t hiu qu tt nht v an ton cho b
They can adjust your dosage or offer further advice to keep your treatment on track and ensure your safety